C3 Reduct (Curcuminoid metabolite)

C3 Reduct is a reduced curcuminoid metabolite derived from Curcumin C3 Complex, composed primarily of tetrahydrocurcumin, tetrahydrodemethoxycurcumin, and tetrahydrobisdemethoxycurcumin. It exerts antioxidant and anti-inflammatory effects by scavenging reactive oxygen species and modulating NF-κB signaling, with potentially superior bioavailability compared to native curcuminoids.

Origin & History

C3 Reduct is a branded ingredient referring to tetrahydrocurcumin (THC), a colorless hydrogenated curcuminoid metabolite derived from enzymatic reduction of curcumin, the primary bioactive compound in turmeric (Curcuma longa rhizomes). It originates from turmeric plants cultivated mainly in India and Southeast Asia, with extraction involving solvent-based isolation of curcuminoids followed by hydrogenation or microbial/enzymatic reduction to produce this more stable metabolite.

Historical & Cultural Context

C3 Reduct lacks traditional use as it is a modern branded metabolite. The parent compound curcumin from turmeric has approximately 4,000 years of history in Ayurveda for inflammation, digestion, skin disorders, and wound healing.

Health Benefits

• No direct clinical evidence exists for C3 Reduct itself - all human trials identified were on related Curcumin C3 Complex
• Parent compound shows modest anti-inflammatory effects in metabolic diseases (evidence quality: moderate from RCTs)
• Preliminary evidence for reducing mesothelioma cell tumorigenicity through impaired self-renewal (evidence quality: preliminary, in-vitro only)
• Parent curcumin showed limited efficacy for psoriasis with only 16.7% response rate in one small RCT (evidence quality: weak)
• Anti-inflammatory effects on IL-6 and anti-dsDNA markers in SLE suggested for curcuminoids (evidence quality: preliminary)

How It Works

C3 Reduct's primary active component, tetrahydrocurcumin, inhibits NF-κB pathway activation by suppressing IκB kinase (IKK) phosphorylation, thereby reducing downstream transcription of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Tetrahydrocurcumin also directly scavenges reactive oxygen species (ROS) via its phenolic hydroxyl groups, exhibiting stronger free-radical quenching activity than parent curcumin in some in vitro models. Additionally, it may modulate Nrf2-Keap1 signaling to upregulate endogenous antioxidant enzymes including superoxide dismutase (SOD) and catalase.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on C3 Reduct (tetrahydrocurcumin) were identified in the research. Evidence is limited to studies on the parent compound Curcumin C3 Complex, including a psoriasis RCT (n=12, terminated early for insufficient efficacy), an Alzheimer's trial (n=36, no efficacy data provided), and metabolic disease RCTs using 150mg twice daily.

Clinical Summary

No published human clinical trials have been conducted specifically on C3 Reduct as an isolated ingredient; existing evidence is extrapolated from studies on its parent compound, Curcumin C3 Complex, and on tetrahydrocurcumin individually. RCTs on Curcumin C3 Complex involving 40–120 participants have demonstrated modest reductions in CRP and IL-6 levels in patients with metabolic syndrome and osteoarthritis, with effect sizes generally considered moderate. In vitro and animal studies on tetrahydrocurcumin suggest superior antioxidant potency and improved plasma half-life compared to curcumin, but these findings have not been confirmed in adequately powered human trials. The overall evidence base for C3 Reduct specifically remains preliminary, and efficacy claims should be interpreted with caution until dedicated clinical data are available.

Nutritional Profile

C3 Reduct is a specialized curcuminoid metabolite preparation, not a whole food ingredient, and therefore lacks conventional macronutrient or micronutrient content in the traditional dietary sense. Its bioactive identity centers on reduced (hydrogenated) curcuminoid derivatives: primarily tetrahydrocurcumin (THC), tetrahydrodemethoxycurcumin, and tetrahydrobisdemethoxycurcumin — the three principal reduced analogs corresponding to the curcuminoids found in Curcumin C3 Complex. Tetrahydrocurcumin typically constitutes the dominant fraction (~75-80% of total reduced curcuminoids by weight in standardized preparations). These compounds are colorless, in contrast to parent curcuminoids, due to saturation of the conjugated double-bond system in the heptadienedione backbone. Protein, fat, carbohydrate, fiber, and micronutrient content are negligible or absent as supplied in extract/supplement form. Bioavailability: tetrahydrocurcumin demonstrates meaningfully improved oral bioavailability relative to native curcumin, attributed to greater metabolic stability (resistance to phase I oxidative metabolism) and enhanced intestinal absorption; animal pharmacokinetic data suggest 4-10x higher plasma AUC compared to equivalent curcumin doses, though robust human pharmacokinetic trials specifically on C3 Reduct branding are limited. The reduced compounds retain phenolic hydroxyl groups relevant to antioxidant activity (DPPH radical scavenging capacity documented in vitro). No caloric contribution is nutritionally meaningful at typical supplemental doses (250-500 mg range).

Preparation & Dosage

No clinically studied dosages for C3 Reduct have been established. Related Curcumin C3 Complex studies used: 4.5g/day for psoriasis, 300mg/day for metabolic conditions. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Piperine (Bioperine), Phospholipids, Black pepper extract, Omega-3 fatty acids, Quercetin

Safety & Interactions

C3 Reduct is generally considered safe at doses comparable to curcuminoid supplementation (500–2000 mg/day of the parent complex), with the most common adverse effects being mild gastrointestinal symptoms including nausea, loose stools, and bloating. Because tetrahydrocurcumin may inhibit CYP3A4 and P-glycoprotein, clinically relevant interactions with anticoagulants such as warfarin, immunosuppressants like tacrolimus, and chemotherapy agents are theoretically possible and warrant medical supervision. C3 Reduct should be used cautiously in individuals with gallbladder disease, as curcuminoids can stimulate bile secretion and potentially exacerbate obstruction. Pregnant and breastfeeding women should avoid supplemental doses beyond dietary levels due to insufficient safety data.